Reata Pharmaceuticals, Inc. (NASDAQ:RETA) SVP Andrea Loewen Sells 3,175 Shares

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) SVP Andrea Loewen sold 3,175 shares of the stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $172.03, for a total value of $546,195.25. Following the completion of the sale, the senior vice president now directly owns 28,416 shares of the company’s stock, valued at $4,888,404.48. The sale was disclosed in a filing with the SEC, which is available at this link.

Reata Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ RETA opened at $172.05 on Tuesday. The stock has a 50 day moving average price of $153.40 and a 200 day moving average price of $114.63. Reata Pharmaceuticals, Inc. has a 52 week low of $21.83 and a 52 week high of $172.15. The company has a debt-to-equity ratio of 0.84, a current ratio of 3.21 and a quick ratio of 3.19.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Tuesday, August 8th. The company reported ($2.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.88) by $0.56. The firm had revenue of $22.75 million for the quarter, compared to the consensus estimate of $0.85 million. Equities analysts forecast that Reata Pharmaceuticals, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RETA. LADENBURG THALM/SH SH downgraded Reata Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $122.00 to $172.50 in a research note on Monday, July 31st. Guggenheim lowered Reata Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Friday, July 28th. Robert W. Baird increased their price objective on Reata Pharmaceuticals from $85.00 to $173.00 and gave the company an “outperform” rating in a report on Monday, July 31st. TD Cowen started coverage on Reata Pharmaceuticals in a report on Thursday, July 6th. They issued an “outperform” rating and a $140.00 target price on the stock. Finally, SVB Leerink raised Reata Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $150.36.

Institutional Investors Weigh In On Reata Pharmaceuticals

Large investors have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its holdings in shares of Reata Pharmaceuticals by 195.2% during the 1st quarter. Nisa Investment Advisors LLC now owns 741 shares of the company’s stock valued at $67,000 after acquiring an additional 490 shares in the last quarter. Suvretta Capital Management LLC bought a new stake in Reata Pharmaceuticals in the 1st quarter valued at about $1,373,000. Altium Capital Management LP bought a new stake in Reata Pharmaceuticals in the 1st quarter valued at about $3,182,000. HAP Trading LLC bought a new stake in Reata Pharmaceuticals in the 1st quarter valued at about $938,000. Finally, First Light Asset Management LLC increased its holdings in Reata Pharmaceuticals by 95.5% during the 4th quarter. First Light Asset Management LLC now owns 2,062,453 shares of the company’s stock worth $78,353,000 after purchasing an additional 1,007,468 shares in the last quarter.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.